Location History:
- North Wales, PA (US) (2018)
- Philadelphia, PA (US) (2020)
Company Filing History:
1 out of 4,456 
1 out of 35 
1 out of 20 
Years Active: 2018-2020
Title: **Innovations of Rodolfo Fleury Perini in Cancer Treatment**
Introduction
Rodolfo Fleury Perini is an accomplished inventor based in Philadelphia, PA, whose work focuses on the intersection of immunotherapy and cancer treatment. With a total of two patents to his name, Perini's contributions stand out in the field of medical research, especially concerning innovative therapies for cancer patients.
Latest Patents
Rodolfo Fleury Perini's most recent patents include groundbreaking combination therapies aimed at improving cancer treatment outcomes. The first patent describes a combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancers that express PD-L1. This therapy leverages the blockade of the Programmed Death 1 receptor (PD-1) alongside a VEGFR inhibitor to enhance anti-tumor responses.
His second patent presents a combination of a PD-1 antagonist with a listeria-based vaccine specifically targeting prostate cancer. This innovative approach involves using a strain that expresses prostate-tissue specific antigen (PSA), enhancing the body’s immune response against prostate cancer cells.
Career Highlights
Throughout his career, Perini has worked with prominent pharmaceutical companies including Pfizer Corporation and Merck Sharpe & Dohme Corp. His experiences at these organizations have likely contributed to his expertise in the development of innovative treatments for cancer.
Collaborations
Rodolfo Fleury Perini has collaborated with notable coworkers, including David J Mauro and Jean-Francois Andre Martini. These partnerships demonstrate his commitment to advancing the field of cancer research through teamwork and shared knowledge.
Conclusion
Rodolfo Fleury Perini exemplifies the spirit of innovation and dedication to improving cancer treatment through his patent-based inventions. His work underscores the importance of combining existing therapies with novel approaches to address critical healthcare challenges, thereby shaping the future of cancer therapy.